Plain-English translation of NCT07287176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the nPulse Vybrance Percutaneous Electrode System, a new device that uses nanosecond pulsed field ablation (a type of energy-based technology) to shrink benign thyroid nodules. The device sends targeted energy pulses through small electrodes to destroy nodule tissue without requiring surgery. Researchers want to see if this treatment can safely reduce nodule size and relieve symptoms like neck discomfort or difficulty swallowing.
Many people have benign (noncancerous) thyroid nodules that cause bothersome symptoms or cosmetic concerns, but current treatment options are limited. This trial exists to determine whether this new energy-based treatment offers a safe, minimally invasive alternative to surgery or other existing therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive at least one treatment with the nPulse Vybrance device, performed as an outpatient procedure using local anesthesia. You may be eligible for a second treatment at the 6-month follow-up visit if your doctor recommends it. You will have ultrasound scans and complete brief questionnaires at 1 month, 3 months, 6 months, and 12 months after treatment to track how your nodule responds.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States